Q-Line Biotech SME IPO Review
Q-Line Biotech SME IPO has been reviewed by 1 analyst, and the overall consensus is May Apply — carrying a score of 60. Out of the 1 analysts who have covered this IPO, 0 recommend subscribing while 1 advises caution or avoidance — reflecting a mixed view from the analyst community.
The issue is priced in the band of ₹326-343 per share, with a minimum application size of 400 shares (minimum investment of approximately ₹137,200 at the upper band). Subscription ran from 21 May 2026 to 25 May 2026. The issue size is ₹251 crore. As of now, the grey market premium (GMP) for Q-Line Biotech SME IPO is quoting at ₹108 (31%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
A written summary will appear here once enough analyst reports are in. Until then, read the analyst-wise verdicts below.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
| Analyst | Verdict | Report |
|---|---|---|
| May Apply |
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Q-Line Biotech SME IPO?
The analyst consensus for Q-Line Biotech SME IPO tracked on this page is May Apply, with a score of 60/100. Out of 1 analyst who have reviewed this IPO, 0 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 60 mean for Q-Line Biotech SME IPO?
The score of 60 is an aggregate of all analyst ratings tracked for Q-Line Biotech SME IPO. A score in this range reflects mixed views — some analysts are positive while others are cautious. Read the individual analyst verdicts above for more context.
What was the actual listing price of Q-Line Biotech SME IPO?
Q-Line Biotech SME IPO listed on May 29, 2026 at ₹452, against the issue price of ₹343 — a gain of +31.78% (₹109 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Q-Line Biotech SME IPO?
Q-Line Biotech SME IPO was priced at ₹326-343 per share. The minimum lot size is 400 shares, making the minimum investment approximately ₹137,200 at the upper end of the price band. Subscription ran from 21 May 2026 to 25 May 2026.
Explore Q-Line Biotech SME IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
